Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapies; An Observational Prospective Study
Isala
776 participants
Sep 1, 2023
INTERVENTIONAL
Conditions
Summary
This study is an interventional, explorative, prospective study to show whether shortening of infusion times for patients using nivolumab, pembrolizumab, ipilimumab, trastuzumab, bevacizumab, durvalumab or atezolizumab continues to be associated with an acceptable safety profile. Infusion times will be gradually shortened if tolerability allowes.
Eligibility
Inclusion Criteria4
- Starting treatment with monoclonal antibodies: nivolumab, pembrolizumab ipilimumab, bevacizumab, trastuzumab, durvalumab or atezolizumab.
- years and older.
- No known history of increased susceptibility to immunological reactions.
- Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.
Exclusion Criteria4
- Other research medication within 4 weeks of the start of the study.
- Inclusion in medical research in which the administration of medication should follow its stated times and dosages of infusions
- Dosage deviates from standard protocol
- Patients whom receive drugs through a central venous catheter (and for example porth-a-cath).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Gradual shortening of infusion times
Gradual shortening of infusion times
Gradual shortening of infusion times
Gradual shortening of infusion times
Gradual shortening of infusion times
Gradual shortening of infusion times
Gradual shortening of infusion times
Gradual shortening of infusion times
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06031233